Bispyridines improve the labeling of nucleophiles, including amines and thiols and are particularly useful for improving labeling with acidic and basic labels. Use of bispyridines with such labels dramatically increases labeling compared to protocols without a bispyridine. The labeled nucleophile can then be subjected to standard analytical methods.

Bispyridines improve the labeling of nucleophiles, including amines and thiols and are particularly useful for improving labeling with acidic and basic labels. Use of bispyridines with such labels dramatically increases labeling compared to protocols without a bispyridine. The labeled nucleophile can then be subjected to standard analytical methods.

Compounds of formula I ##STR00001##
their use in liquid-crystalline media, for example, for the phase shifting of microwaves for tunable phased-array antennae, and their use for high-frequency components, in particular antennae, especially for the gigahertz range.

Compounds of formula I ##STR00001##
their use in liquid-crystalline media, for example, for the phase shifting of microwaves for tunable phased-array antennae, and their use for high-frequency components, in particular antennae, especially for the gigahertz range.

Disclosed are compounds, for example, a compound of formula I, wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

##STR00001##

Disclosed are compounds, for example, a compound of formula I, wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

##STR00001##

Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

##STR00001##

Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

##STR00001##

A solid fuel boiler with one or more fuel chutes configured to pre-dry wet solid fuel prior to loading into a combustion chamber of the boiler, enabling higher thermal efficiencies and burning less fuel to produce the same steam quantity. The pre-drying fuel chutes pass through the boiler where hot combustion gases radiantly and convectivelyheat the chute walls to dry the wet solid fuel by radiant, convective, and/or conductive heating. Agitator mechanisms or structures within the chute mix the fuel for uniform heating, break up clumps of wet fuel, regulate the speed of falling fuel, prevent sticking, dry the fuel by means of steam and/or hot air, transport and deliver a cooling medium while a chute is offline in an operating boiler, and suppress fire using steam injection. Fuel from the chute can flow into a fuel storage bin or directly into the combustion zone of the furnace.

An iridium complex compound represented by formula (1) below.

##STR00001## R.sup.2 to R.sup.5 are each selected from a [substituent group W]; R.sup.1, R.sup.6 to R.sup.10, and R.sup.14 are a hydrogen atom, F, a methyl group, a trifluoromethyl group, an ethyl group, a vinyl group, or an ethynyl group; R.sup.15 and R.sup.16 are a linear, branched, or cyclic alkyl group having 1 to 30 carbon atoms, an aralkyl group having 5 to 60 carbon atoms, or a heteroaralkyl group having 5 to 60 carbon atoms; one of R.sup.11 to R.sup.13 has a structure represented by formula (2) below; and the remaining two are selected from a [substituent group Z].

##STR00002##